Dawnrays Pharmaceutical (02348) said its profit attributable to owners of the parent for the six months ended 30 June 2017 rose 13.3% year-on-year to Rmb149 million.
Basic and diluted earnings per share were Rmb18.59 cents.
Revenue amounted to Rmb491 million, an increase of 17.4% from a year earlier.
Gross profit grew 33.3% year-on-year to Rmb341 million. Gross profit margin was 69.4% which was increased by 8.3 percentage points compared with 61.1% as in the corresponding period of last year.
The increase in turnover and profit was mainly due to the remained good trend of sales of the Group's specific medicines.
The proposed interim dividend is HK3 cents (2016: HK3 cents) per share, payable on or about 28 September.